[1] Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.   doi: 10.3322/caac.214420010
[2] Sauer R, Becker H, Hohenberger W, et al.  Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer[J]. N Engl J Med, 2004, 351(17): 1731-1740.   doi: 10.1056/NEJMoa040694
[3] Wolmark N, Wieand HS, Hyams DM, et al.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02[J]. J Natl Cancer Inst, 2000, 92(5): 388-396.   doi: 10.1093/jnci/92.5.388
[4] Sunshine J, Taube JM.  PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol, 2015, 23: 32-38.   doi: 10.1016/j.coph.2015.05.011
[5] Thara E, Barzi A.  Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy[J]. Curr Colorectal Cancer Rep, 2015, 11(2): 84-91.   doi: 10.1007/s11888-015-0260-y
[6] Tanaka T, Kohno H, Suzuki R, et al.  A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate[J]. Cancer Sci, 2003, 94(11): 965-973.   doi: 10.1111/j.1349-7006.2003.tb01386.x
[7] Natarajan A, Mayer AT, Xu LY, et al.  Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes[J]. Bioconjug Chem, 2015, 26(10): 2062-2069.   doi: 10.1021/acs.bioconjchem.5b00318
[8] England CG, Jiang DW, Ehlerding EB, et al.  89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer[J]. Eur J Nucl Med Mol Imaging, 2018, 45(1): 110-120.   doi: 10.1007/s00259-017-3803-4
[9] Li DN, Wang C, Zhang DK, et al.  Preliminary Application of 125I-Nivolumab to Detect PD-1 Expression in Colon Cancer via SPECT[J]. J Radioanal Nucl Chem, 2018, 318(2): 1237-1242.   doi: 10.1007/s10967-018-6124-6
[10] 李囡, 林保和, 杨志, 等.  CD20阳性B细胞NHL131I-美罗华放射免疫治疗剂量个体化的临床初步研究[J]. 同位素, 2004, 17(4): 204-209.   doi: 10.3969/j.issn.1000-7512.2004.04.003
Li N, Lin BH, Yang Z, et al.  The Primary Clinical Study on Individual Radioimmunotherapy Protocol With 131I-Rituximab for CD20 Positive B Cell Non-Hodgkin's Lymphoma[J]. J Isotopes, 2004, 17(4): 204-209.   doi: 10.3969/j.issn.1000-7512.2004.04.003
[11] Ychou M, Pelegrin A, Faurous P, et al.  Phase-I/Ⅱ radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer[J]. Int J Cancer, 1998, 75(4): 615-619.   doi: 10.1002/(SICI)1097-0215(19980209)75:4<615::AID-IJC20>3.0.CO;2-6
[12] Maier P, Hartmann L, Wenz F, et al.  Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization[J]. Int J Mol Sci, 2016, 17(1): -.   doi: 10.3390/ijms17010102